Outlook Therapeutics requests Type A meeting with FDA following second CRL for ONS-5010

Published on September 3, 2025
Outlook Therapeutics seeks FDA clarity on ONS-5010 after a complete response letter, aiming to address efficacy concerns for wet AMD treatment.
Continue reading on website
Other news

The optometric community reflects on the late Richard Hopping, OD, and his legacy

September 3, 2025
The optometric giant recently passed away at 97 years old.

American Academy of Optometry Announces 2025 Award Recipients

September 4, 2025
WINTER PARK, Fla.—The American Academy of Optometry (AAO) has announced its 2025 award recipients, continuing its annual tradition of recognizing individuals who have made important contributions to advancing the profession of optometry, the Academy said. “The Academy’s prestigious awardees are nominated by Fellows who have been inspired by the exceptional strides these individuals have made in th